相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity
Steven M. Offer et al.
CANCER RESEARCH (2013)
A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity
S. M. Offer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues
Takeshi Hirota et al.
LUNG CANCER (2012)
Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer
Patrice Cellier et al.
BMC CANCER (2011)
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity
Chen Guang Yang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
Maarten J. Deenen et al.
CLINICAL CANCER RESEARCH (2011)
Pharmacogenetics: From Bench to Byte-An Update of Guidelines
J. J. Swen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity
Ursula Amstutz et al.
PHARMACOGENOMICS (2011)
Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene
Anna Ofverholm et al.
CLINICAL BIOCHEMISTRY (2010)
Inborn errors of purine and pyrimidine metabolism
A. Jurecka
JOURNAL OF INHERITED METABOLIC DISEASE (2009)
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment
Ursula Amstutz et al.
PHARMACOGENOMICS (2009)
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer
Erick Gamelin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group
Matthias Schwab et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients
Y. -F. He et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2008)
The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer
O. Capitain et al.
PHARMACOGENOMICS JOURNAL (2008)
Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population
Radhia Ben Fredj et al.
COMPTES RENDUS BIOLOGIES (2007)
Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences
Keiko Maekawa et al.
JOURNAL OF HUMAN GENETICS (2007)
5-fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency
M. Boisdron-Celle et al.
CANCER LETTERS (2007)
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
Alain Morel et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometry
C Schmidt et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2005)
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells
T Noguchi et al.
CLINICAL CANCER RESEARCH (2004)
Detailed Analysis of Five Mutations in Dihydropyrimidine Dehydrogenase Detected in Cancer Patients With 5-fluorouracil-related Side Effects
Eva Gross et al.
HUMAN MUTATION (2003)
High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity
ABP van Kuilenburg et al.
PHARMACOGENETICS (2002)
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency:: High prevalence of the IVS14+1G>A mutation
ABP Van Kuilenburg et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
分享论文
